Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Windtree Therapeutics: Phase 2b Trial Fails Although There Was An Encouraging Signal of Activity (WINT, Take tax loss, $0.34)

Key Points:

The phase 2b trial failed, but there was an encouraging signal of activity.
The failure was related to…
Read more…

Windtree Therapeutics: Thinking About the Stock Price After Phase 2b Results for Aerosurf in RDS Are Released In July (WINT, $0.92)

Investment Thesis

Windtree is facing the ultimate of binary events when it releases topline results in July for its critical phase…
Read more…

Windtree Therapeutics: Key Points from Conference Call on 1Q, 2016 Results (WINT, $2.04)

Investment Thesis

The current market valuation of Windtree is only $16 million. This seems extremely low for a Company that…
Read more…